



Role of T cell-derived exosomes in immunoregulation

Jian Lu^{1,2} · Jing Wu^{1,2} · Jie Tian^{2,3} · Shengjun Wang^{1,2} 

Published online: 26 May 2018

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Abstract

Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells. They are composed of a lipid bilayer containing transmembrane proteins and enclosing cytosolic proteins and RNA, mediating intercellular communication between different cell types in the body, and thus influencing various physiological and pathological functions of both recipient and parent cells. For their nanolevel structures with a stable nature and various biological functions, studies of exosomes have been the subject of increasing interest in the past few years. It is widely known that different T cell subsets play important roles in cellular and humoral immunity, and their exosomes were also reported to exert similar biological functions. While several groups reported the secretion of exosomes by various T cells, the systematic summary involved in these exosomes are deficient. In this review, we will summarize the structure and functions of exosomes derived from T cells in recent reports, discuss emerging therapeutic opportunities, and consider the associated challenges.

Keywords T cells · Exosomes · Immune regulation

Introduction

T cells play central roles in cell-mediated and humoral immunity. Several different subsets of T cells have been discovered, each with distinct functions. According to the phenotype, T cells can mainly be divided into CD4⁺ helper T cells and CD8⁺ cytotoxic T cells. CD4⁺ T cells can be further divided into Th1, Th2, Th9, Th17, Th22, follicular helper T cells (Tfh), and regulatory T cells (Tregs), each of which produces specific effector cytokines under unique transcriptional regulation [1–7]. Intercellular communication is an essential hallmark of multicellular organisms and can be mediated through direct cell–cell contact or transfer of secreted molecules [8]. In 1983,

exosomes were first found in the reticulocytes of sheep, and they were named “exosomes” by Johnstone in 1987 [9]. Increasing evidences have shown that the transfer of exosomes from one cell to another, as another novel mechanism of cell signal transduction, plays an increasingly important role in intercellular communication [10–12]. It has been well established that almost all living cells can secrete exosomes. These nanometer-sized particles can selectively carry proteins and RNA from their origin cells, thus exert their biological functions. Mostly, functions of these exosomes are similar to their sources, but they can also be diverse depending on the state of the origin cells [13]. These small vesicles can be taken up by target cells via different manners, such as direct membrane fusion, phagocytosis, endocytosis, and even pinocytosis [14]. The biological functions of exosomes can also behave in different ways. For instance, exosomes can regulate the expression of target protein by carrying mRNAs which can be translated into the corresponding protein, by carrying miRNAs that can degrade the intracellular mRNA of that protein, or by carrying siRNAs that can silence the gene corresponding to that protein [15–17]. With increasing numbers of studies on exosomes, functions of exosomes derived from T cells have largely been unearthed, such as effectively activating or suppressing the immune response, promoting the inflammatory response, and participating in autoimmune and infectious diseases [18, 19]. In this review, we will especially focus on the structural features and major surface markers of T

✉ Jie Tian
tjj850913@163.com

✉ Shengjun Wang
sjwjs@ujs.edu.cn

¹ Department of Laboratory Medicine, The Affiliated People's Hospital, Jiangsu University, Dianli Road No. 8, Zhenjiang 212012, China

² Department of Immunology, Jiangsu Key Laboratory of Laboratory Medicine, Jiangsu University School of Medicine, Zhenjiang, China

³ Institute of Laboratory Medicine, Jiangsu University School of Medicine, Zhenjiang 212013, China

cell-derived exosomes. We also further introduce their roles in mediating immune regulation and provide new ideas for the future treatment of autoimmune diseases and cancers.

The role of exosomes in immune system

In immune system, exosomes possess immunomodulatory properties, including antigen presentation, immune promotion, immune suppression, and immune tolerance. For their functions in antigen presentation, exosomes loaded with specific peptides or antigens are capable of promoting the activation of CD4⁺ T cells and CD8⁺ T cells, even in the absence of dendritic cells (DCs) [20]. In addition, exosomes derived from macrophages are able to transfer their surface antigens to DCs, thus enhancing the response of CD4⁺ T cells [21]. What is more, after presenting antigens, DCs can also secrete exosomes to further activate CD4⁺ T cells, CD8⁺ T cells, and natural killer cells (NK cells) in an antigen-specific manner [22–24]. Recently, exosomes have been demonstrated to be involved in the proinflammatory response and the enhancement of immune function [25–28]. For instance, exosomes released by virus-infected macrophages can promote TNF- α secretion of macrophages and neutrophils. Moreover, pathogen-associated molecular patterns (PAMPs) on the surface of exosomes can also strengthen immune surveillance [29]. Clinical studies have also found that there are large amounts of exosomes in the bronchoalveolar lavage fluid of patients with sarcoidosis. These exosomes can significantly induce IFN- γ and interleukin (IL)-13 production in autologous PBMCs and stimulate epithelial cells to produce IL-8, which may contribute to the initiation of inflammation [30]. In addition, exosomes in the synovial fluid of patients with rheumatoid arthritis have also been reported to boost the immune inflammatory reaction and aggravate the disease process [31]. Recently, researches on the immunosuppressive functions of exosomes mainly concentrate on tumor cells and several immunosuppressive cells. Studies have already shown that exosomes derived from tumor cells can impair T cells, B cells, monocytes/macrophages, NK cells, and DC functions and even promote the proliferation of myeloid-derived suppressor cells (MDSCs) [32–37]. MDSCs are a heterogeneous immature myeloid cells that possess immunosuppression [38]. Interestingly, Wang and his colleagues found that MDSC-derived exosomes can attenuate dextran sodium sulfate-induced colitis by inhibiting the Th1 immune response [39]. Simultaneously, Treg-derived exosomes have received widespread attention for their ability to exert immunosuppressive effects, which can prolong survival in a kidney allograft rat model [40].

The composition of exosomes

According to the current version of the exosomes database, Exocarta (<http://www.exocarta.org>), more than 9700 proteins have been found in exosomes, including cytoplasmic proteins, membrane proteins, Golgi-associated proteins, and endoplasmic reticulum-related proteins [41–43]. In addition, other metabolism-related enzymes, signal transduction proteins, carrier proteins, and some histocompatibility antigens are also widely found in exosomes [42].

Exosomes have a membrane structure that is rich in lipids. However, the lipid composition of exosomes differs from that of their source cells. There is much more sphingomyelin, phosphatidylserine, phosphatidylinositol, ceramide, and cholesterol in exosomes than in source cells, while source cells contain a higher proportion of phosphatidylcholine [44]. More interestingly, exosomes have the highest lipid packing density when compared to other extracellular vesicles, which shows that the structure of exosomes may be more stable [45].

Moreover, a major characteristic of exosomes that can distinguish them from other biological vesicles is that exosomes are rich in a large number of nucleotides, mainly including microRNAs and mRNAs [46]. In addition, exosomes also contain variety of other RNA species, including RNA transcripts overlapping with protein coding regions, repeat sequences, structural RNAs, tRNA fragments, vault RNA, Y RNA, circular RNA, and small-interfering RNAs [47–49].

The biological characteristics of exosomes

Studies have confirmed that surface markers of exosomes can be analyzed *in vitro* and their contents are quite stable [49, 50]. DC-derived exosomes can carry many effector molecules, such as MHC-I and MHC-II molecules, which could potentially stimulate CD8⁺ and CD4⁺T cells, respectively, as well as other costimulatory molecules [51–53], which means that exosomes are capable of sharing the faculties of their original cells. In addition, exosomes are able to reach a wide range of lymphoid organs through contact with corresponding cells, and exosomes are independent of chemokines [54, 55]. It was reported that high expression of fluorescence can be detected in the lung, liver, spleen, pancreas, GI tract, and kidneys in a dose-dependent manner 24 h after the intravenous injection of fluorescence-labeled exosomes [55]. These data demonstrated that the distribution of exosomes is rapid and extensive, which means that the biological effects of exosomes may also diverse *in vivo*. More importantly, exosomes prepared *in vitro* can be stored at $-80\text{ }^{\circ}\text{C}$ for a long time and have no response to several associated immunosuppressive molecules [56]. Through the studies of biological characteristics of exosomes, it may provide the great directive significance to further clinical applications.

The surface molecules of T cell-derived exosomes

There are many function-related molecules in the membranes of T cells, which are involved in cells activation, proliferation, differentiation, antigen presentation, and effector functions. Interestingly, these molecules are also found to be expressed on T cell-derived exosomes.

The membrane of T cell-derived exosomes is a lipid bilayer that is commonly enriched in a set of proteins involved in the processes mentioned above. These small vesicles can express CD2, CD3/TCR, CD4, CD8, CD11c, CD25, CD69, LFA-1, CXCR4, FASL, GITR, etc. (Fig. 1).

The functions of T cell-derived exosomes

In vitro studies have shown that T cells that were co-stimulated with TCR and CD28 can secrete more exosomes in vitro [57]. Moreover, T cells are able to regulate the release of distinct exosomes subpopulations depending on their activation status [58]. However, other activators such as PMA and ionomycin fail to promote the secretion of exosomes, which indicates that exosomes secretion may be related to a kind of physiological response occurring [59]. In the following discussion, we will further summarize different functions of T cell-derived exosomes (Fig. 2).

The immunosuppressive effects of T cell-derived exosomes

Tregs are a subset of T cells with immunosuppressive functions [60]; more and more studies have focused on Treg-derived exosomes due to their considerable immunosuppressive effects, which can also be useful when considering possible therapeutic tools in autoimmune diseases and transplantation [61]. Interestingly, it is reported that Tregs can secrete more exosomes than other T cells, and the surfaces of those exosomes mainly express CD25, CTLA-4, and CD73. Specifically, CD73-expressing exosomes perform immunosuppressive functions through the production of adenosine, which plays an important role in the anti-inflammatory response [62–64]. They can also carry let-7b, let-7d, and microRNA-155, which can inhibit the Th1 immune response and mediate immune suppression [18]. With in-depth studies on the biogenesis of exosomes, multivesicular body (MVB)-dependent secretion may be one of the most important pathways in exosome secretion. Proteins of the Ras-related proteins in brain (RAB) family, such as RAB11, RAB35, RAB7, RAB27A, and RAB27B, have been shown to be involved in exosome secretion in tumor cell lines of various origins [65–69]. Interestingly, It was shown that Rab27-DKO Tregs failed to release exosomes and thus failed to suppress Th1




Fig. 1 Typical surface molecular of T cell-derived exosomes. Important membrane molecules found in a typical exosomes produced by T cells. GITR glucocorticoid-induced tumor necrosis factor receptor, MHC I/II major histocompatibility complex I/II, LFA-1/2 lymphocyte function-associated antigen 1/2, TSG101 tumor susceptibility gene 101; FasL Fas ligand or CD95L, CXCR4 C-X-C chemokine receptor type 4 or CD184, TCR T-cell receptor. For more information about exosome composition, please see <http://www.exocarta.org> or <http://www.microvesicles.org>

cells [18], which mean that the proteins of RAB family also play a significant role in exosomes secretion in T cells. However, although the immunosuppressive functions of Treg-derived exosomes are quite strong, the specific mechanism is still unknown. Besides adenosine converted by CD73 and some miRNAs mentioned above, IL-10 and TGF- β may be two additional important negative regulatory factors [70, 71]. Nevertheless, it is unknown whether these cytokines are contained in Treg-derived exosomes. However, we believe that this assumption was established based on the fact that several cytokines were found in exosomes, and DC-derived exosomes were reported to contain IL-10 and TGF- β [72, 73]. In conclusion, Treg-derived exosomes show great potential for regulating the body's immunity and can further be applied to inhibit the graft rejection. In fact, Yu and colleagues have already observed that the adoptive transfer of autologous Treg-derived exosomes from rats can strengthen kidney function and prolong the survival of kidney allografts post-transplantation [40].

The immunological synapse between T cells and antigen presenting cells (APCs) was reported to promote the efficiency of exosomes transfer [19]. Exosomes can be taken up by DCs via peptide/major histocompatibility complex (pMHC)-II/TCR and CD54/LFA-1 interactions. The surface molecule FasL can bind its receptor Fas on DCs, which leads to the




Fig. 2 The immunoregulation of T cell-derived exosomes. Different subtypes of T cells can secrete their own exosomes. CD3⁺ T cells can take up their own exosomes to promote the proliferation by an autocrine manner. Exosomes derived from CD4⁺ T cells and CD8⁺ T cells can bind to dendritic cells through peptide/major histocompatibility complex MHC/TCR and ICAM-1/LFA-1 interactions, which lead to the apoptosis of

dendritic cells (DCs) by Fas/FasL and thus mediate the DC-mediated T cell silencing in an antigen-specific way. For regulatory T cells, they can secrete exosomes which contain Let-7b, Let-7d, and microRNA-155 to inhibit Th1 immune response and mediate immune suppression. In addition, CD73-expressing Treg-derived exosomes are able to produce adenosine which may further inhibit the activation and proliferation of CD4⁺ T cells

apoptosis of DCs and mediates the silencing of the T cell response in an antigen-specific way [74]. Interestingly, recent studies have also shown that CD8⁺ T cell-derived exosomes can regulate the functions of target cells, and these exosomes can be endocytosed by APCs and B cells via pMHC-I/TCR interactions and inhibit antigen-specific DCs mediated CD8⁺ CTL responses. In addition, these exosomes can also inhibit anti-tumor immunity and diabetes in an antigen-dependent way [75]. Furthermore, macrophages cultured with CD8⁺ T cell-derived exosomes lost contact sensitivity (CS), which may be related to the induction of Tregs and inhibition of effector T cells proliferation [76]. Moreover, by carrying miRNA-150 and transferring it to effector T cells, antigen-specific CD8⁺ T cell-derived exosomes can mediate immunosuppressive function and inhibit experimental allergic contact dermatitis induced in mice by high doses of reactive haptens. When miRNA-150 was knocked down, this phenomenon disappeared, which suggested that microRNA-containing exosomes may also play a significant role in intercellular communication of lymphocytes [77]. However, determining the

function of these exosomes merely by focusing on single or several molecules on their surface is unreasonable and ambiguous, especially on lymphocytes, exosomes induce diverse immune responses dependent on the different cells they are targeting. Moreover, several other factors can play a role in the final immunological effect of an exosome, including other molecules on the exosomes surface, other types of RNA in the exosomes, and even some kinases in exosomes that can directly activate target cells [78]. As a result, further studies are needed to figure out what exact functions exosomes have.

T cell-derived exosomes in promoting immune responses

We have mentioned that T cells can secrete more exosomes when co-stimulated with TCR and CD28. Valadi and his colleagues documented that CD3⁺ T cell-derived exosomes were involved in the stimulation and proliferation of resting CD3⁺ T cells. When together with IL-2, the CD3⁺ T cell-derived exosomes can induce a relative increase of CD8⁺ T cells,

which is similar to what would be seen with IL-2 combined with anti-CD3 and anti-CD28 mAbs. Moreover, the authors also showed that these exosomes may contain CCL5 (RANTES), which has major effects on HIV inhibition [79]. CD8⁺ T cells were first confirmed to secrete secretory lysosomes, which can carry granzyme, perforin, and other effector molecules and which play an important role in the specific delivery of cytolytic molecules to target cells [80]. Coincidentally, exosomes derived from CD8⁺ T cells were proved to suppress the CCR5-tropic (R5) and CXCR4-tropic (X4) replication of HIV-1 in vitro [81]. This evidence indicated that there is an intracellular signaling mechanism involved in the exosomes-mediated suppression of HIV-1 transcription, which could be of potential interest for anti-viral treatment. Overall, the studies on the immunological enhancement of T cells are insufficient. The contradiction is that most T cell subtype-derived exosomes show more immunosuppressive properties, which are inconsistent with their source cells' function. This phenomenon may be related to the different target cells they interact with. When CD4⁺ T cells interact with DCs through (pMHC)-II/TCR and CD54/LFA-1, FasL can be the main effector molecule, thus leading to the apoptosis of DCs and silencing of the T cell response. However, as a traditional group of helper T cells, CD4⁺ T cells also highly express CD40L and ICOS after activation [82, 83]. The consequences may be different when their exosomes are taken up by B cells. Whether CD4⁺ T cell-derived exosomes can carry related effector molecules to activate B cells and promote humoral immunity remains to be further studied.

T cell-derived exosomes in tumor

Studies have also shown that T cell-derived exosomes may be involved in the progression of tumor formation or tumor invasion. Exosomes from activated CD8⁺ T cells were shown to activate ERK and NF- κ B in melanoma cells, leading to increased MMP9 expression and promoting cancer cell invasion in vitro, suggesting a role for T cell-derived exosomes in tumor progression [84]. Using a Jurkat T cell line to study natural T cells, Roberts and his colleagues discovered that T cell-derived exosomes can alter endothelial gene expression and physiological processes, such as regulating endothelial cell proliferation and vascular endothelial growth factor (VEGF) signaling in a CD47-dependent manner [85], which means that CD47-positive exosomes may also modulate tumor angiogenesis. In addition, Sun reported that exosomes derived from irradiated esophageal carcinoma-infiltrating T cells could promote the metastasis of esophageal cancer cells by inducing epithelial mesenchymal transition [86]. These studies all documented that T cell-derived exosomes may play an important role in tumor formation and invasion. However, although Jurkat cells are characterized as immortalized T cells, the biological characteristics of Jurkat cells and human natural

T cells are not entirely consistent. For example, experiments have proven that only 40% of proteins are shared between these two exosomes according to proteomic analysis [87]. As a result, many more studies are needed to confirm the precise biological functions of T cell-derived exosomes.

Reflections on T cell-derived exosomes

A large amount of studies have showed that exosomes can also be used as biological markers for clinical diagnosis. They can be detected in patient biofluids including serum, urine, semen, saliva, and bronchoalveolar lavage [88–92]. For example, in the early stages of tumor formation, cancer cell-derived exosomes, which play an important role in tumor immune escape, angiogenesis, and invasiveness [93, 94], can be detected in the peripheral blood, suggesting that tumor exosomes can act as a biomarker for early tumor screening [95]. T cell-derived exosomes can also be used as early markers of disease development, for example, high concentrations of CD4⁺ T cell-derived and CD8⁺ T cell-derived exosomes were detected in serum from the peripheral blood of chronic hepatitis B patients, while patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis had high levels of invariant natural killer T (iNKT) cell-derived and macrophage/monocyte-derived exosomes [96].

The latest studies on exosomes showed that donor exosomes, rather than passenger leukocytes, could initiate alloreactive T cell response after transplantation, which showed the rapid and efficient function of exosomes in immunoregulation [97]. For T cell-derived exosomes, Treg-derived exosomes have been shown to mediate immunosuppressive effects and to be effective in inhibiting the development of murine arthritis, and their clinical value has been extensively discussed [61]. In addition, CD4⁺ T cell-derived exosomes can specifically inhibit CD4⁺ T cell proliferation and CD8⁺ CTL responses, which provide the potential possibility of CD4⁺ T cell-derived exosomes being used for the treatment of autoimmune diseases and as preventers of immune rejection. Currently, chimeric antigen receptor gene-modified T (CAR-T) cells have been widely recognized as a novel form of viable tumor treatment by the medical community for their exciting efficacy in blood cancer therapies. Although the treatment showed unprecedented efficacy in hematologic malignancies, some problems still exist in CAR-T cell treatments. These problems include CAR-T cell-induced cytokine release syndrome (CRS), which can lead to hypotension, nausea, tachycardia, headache, rash, and shortness of breath caused by the release of cytokines from immune cells after the treatment. CAR-T cell therapies can even lead to high fever, hypotension, organ failure, and death [98]. As a consequence, some scholars propose the application of CAR-T cell-derived exosomes in cancer therapy. First, modified CAR-T cell-

derived exosomes may kill target cells by granzymes and lysosomal enzymes. It is known that the biological effect of granzymes is dependent on perforin which polymerizes in the cell membrane to form a nonspecific ion pore [99]. However, exosomes can directly transfer these granzymes by membrane fusion with target cells or be endocytosed [80]. In addition, for its nonliving property, CAR-T cell-induced toxicity can be more easily controlled by using CAR-T cell-derived exosomes than traditional treatment. Second, exosomes, as a kind of small nanometer-sized particles, can easily cross biological barriers such as the blood–brain barrier (BBB) and blood–tumor barrier (BTB) [100]. Moreover, CAR-T cell-derived exosomes show greater potential in penetrating the extracellular matrix (ECM) of a solid tumor than CAR-T cells, which means that these small nanometer-sized particles may be more helpful in treating solid tumor and brain tumor. Third, since exosomes resemble liposomes consisting of a bi-lipid membrane and an aqueous core, anti-cancer agents can be directly loaded into CAR-T cell-derived exosomes which can be used to kill target cells [101].

As discussed, although numerous researches have focused on exosomes, the structure, formation, secretion, and their function are still unclear. Especially for T cells and other original lymphocytes derived exosomes, because of the difficulty of obtaining a mass of high-purity cells, diverse responses to different stimulations, and a great diversity of cell subsets, the researches about T cell-derived exosomes are limited. In general, there are still insufficient findings on exosomes derived from T cells, and much more remains to be confirmed by extensive experimental studies.

At present, many studies have focused on the regulation of T and B cells by other nonlymphoid cells, such as DC-derived exosomes, mesenchymal stem cell (MSC)-derived exosomes, and tumor cell-derived exosomes. However, the communication between lymphocytes via exosomes must also exist, and the effects of these exosomes may be more specific and more powerful. For B cell-derived exosomes, it was shown that they are involved in antigen presentation, leading to the activation of primed CD4⁺ T cells and antigen-specific T cells [102, 103]. Additionally, a strong cytotoxic effect on several kinds of tumor cells and immune cells has been observed with NK cell-derived exosomes [104]. Therefore, through the study of T cell or other lymphocyte-derived exosomes, it may have a directive and practical importance to utilize artificially modified exosomes to treat autoimmune diseases and cancers.

Author contributions JL discussed the ideas, wrote, and discussed the text with other authors. JW and JT discussed the text with other authors. SW conceived the idea and topic of the review, read, and made suggestions in the final text.

Funding information This work was supported by the National Natural Science Foundation of China (Grant Nos. 81771759, 31470881,

31711530025), Natural Science Foundation of Jiangsu (Grant No. BK20150533), Project funded by China Postdoctoral Science Foundation (Grant Nos. 2016 M590423, 2017 T100336), Jiangsu Province's Key Medical Talents Program (Grant No. ZDRCB2016018), Summit of the Six Top Talents Program of Jiangsu Province (Grant No. 2015-WSN-116), and Jiangsu Province "333" Project (Grant No. BRA2017128).

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests.

References

- Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. *J Immunol* (Baltimore, Md: 1950). 2005;175(1):5–14.
- Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol*. 2005;6(11):1123–32. <https://doi.org/10.1038/ni1254>.
- Liu Y, Tang X, Tian J, Zhu C, Peng H, Rui K, et al. Th17/Treg cells imbalance and GITRL profile in patients with Hashimoto's thyroiditis. *Int J Mol Sci*. 2014;15(12):21674–86. <https://doi.org/10.3390/ijms151221674>.
- Chang HC, Sehra S, Goswami R, Yao W, Yu Q, Stritesky GL, et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. *Nat Immunol*. 2010;11(6):527–34. <https://doi.org/10.1038/ni.1867>.
- Bryant VL, Ma CS, Avery DT, Li Y, Good KL, Corcoran LM, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5⁺ T follicular helper cells. *J Immunol* (Baltimore, Md: 1950). 2007;179(12):8180–90.
- Zhu C, Ma J, Liu Y, Tong J, Tian J, Chen J, et al. Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. *The Journal of Clinical Endocrinology Metabolism*. 2012;97(3):943–50. <https://doi.org/10.1210/jc.2011-2003>.
- Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, et al. TGF-beta 1 plays an important role in the mechanism of CD4⁺CD25⁺ regulatory T cell activity in both humans and mice. *J Immunol* (Baltimore, Md: 1950). 2004;172(2):834–42.
- Singer SJ. Intercellular communication and cell-cell adhesion. *Science* (New York, NY). 1992;255(5052):1671–7.
- Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J Biol Chem*. 1987;262(19):9412–20.
- Buschow SI, Nolte-t' Hoen EN, van Niel G, Pols MS, ten Broeke T, Lauwen M, et al. MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. *Traffic* (Copenhagen, Denmark). 2009;10(10):1528–42. <https://doi.org/10.1111/j.1600-0854.2009.00963.x>.
- Rana S, Yue S, Stadel D, Zoller M. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. *Int J Biochem Cell Biol*. 2012;44(9):1574–84. <https://doi.org/10.1016/j.biocel.2012.06.018>.
- Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, et al. Mechanism of transfer of functional

- microRNAs between mouse dendritic cells via exosomes. *Blood*. 2012;119(3):756–66. <https://doi.org/10.1182/blood-2011-02-338004>.
13. Aliotta JM, Pereira M, Li M, Amaral A, Sorokina A, Dooner MS, et al. Stable cell fate changes in marrow cells induced by lung-derived microvesicles. *J Extracell Vesicles*. 2012;1 <https://doi.org/10.3402/jev.v1i0.18163>.
 14. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. *J Extracell Vesicles*. 2014;3 <https://doi.org/10.3402/jev.v3.24641>.
 15. Kapoor NR, Chadha R, Kumar S, Choedon T, Reddy VS, Kumar V. The HBx gene of hepatitis B virus can influence hepatic micro-environment via exosomes by transferring its mRNA and protein. *Virus Res*. 2017;240:166–74. <https://doi.org/10.1016/j.virusres.2017.08.009>.
 16. Wei F, Ma C, Zhou T, Dong X, Luo Q, Geng L, et al. Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p. *Mol Cancer*. 2017;16(1):132. <https://doi.org/10.1186/s12943-017-0694-8>.
 17. Zhang H, Wang Y, Bai M, Wang J, Zhu K, Liu R, et al. Exosomes serve as nano-particles to suppress tumor growth and angiogenesis in gastric cancer by delivering HGF siRNA. *Cancer Sci*. 2017;109:629–41. <https://doi.org/10.1111/cas.13488>.
 18. Okoye IS, Coomes SM, Pelly VS, Czieso S, Papayannopoulos V, Tolmachova T, et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. *Immunity*. 2014;41(1):89–103. <https://doi.org/10.1016/j.immuni.2014.05.019>.
 19. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, Gonzalez MA, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. *Nat Commun*. 2011;2:282. <https://doi.org/10.1038/ncomms1285>.
 20. Admyre C, Johansson SM, Paulie S, Gabrielsson S. Direct exosome stimulation of peripheral human T cells detected by ELISPOT. *Eur J Immunol*. 2006;36(7):1772–81. <https://doi.org/10.1002/eji.200535615>.
 21. Xu Y, Liu Y, Yang C, Kang L, Wang M, Hu J, et al. Macrophages transfer antigens to dendritic cells by releasing exosomes containing dead-cell-associated antigens partially through a ceramide-dependent pathway to enhance CD4(+) T-cell responses. *Immunology*. 2016;149(2):157–71. <https://doi.org/10.1111/imm.12630>.
 22. Liu H, Gao W, Yuan J, Wu C, Yao K, Zhang L, et al. Exosomes derived from dendritic cells improve cardiac function via activation of CD4(+) T lymphocytes after myocardial infarction. *J Mol Cell Cardiol*. 2016;91:123–33. <https://doi.org/10.1016/j.yjmcc.2015.12.028>.
 23. Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, et al. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. *PLoS One*. 2008;3(10):e3377. <https://doi.org/10.1371/journal.pone.0003377>.
 24. Bu N, Wu H, Zhang G, Zhan S, Zhang R, Sun H, et al. Exosomes from dendritic cells loaded with chaperone-rich cell lysates elicit a potent T cell immune response against intracranial glioma in mice. *J Mol Neurosci* : MN. 2015;56(3):631–43. <https://doi.org/10.1007/s12031-015-0506-9>.
 25. Fang H, Shao S, Jiang M, Dang E, Shen S, Zhang J, et al. Proinflammatory role of blister fluid-derived exosomes in bullous pemphigoid. *J Pathol*. 2018;245:114–25. <https://doi.org/10.1002/path.5061>.
 26. Singhto N, Kanlaya R, Nilnumkhum A, Thongboonkerd V. Roles of macrophage exosomes in immune response to calcium oxalate monohydrate crystals. *Front Immunol*. 2018;9:316. <https://doi.org/10.3389/fimmu.2018.00316>.
 27. Wahlund CJE, Gucluler G, Hiltbrunner S, Veerman RE, Naslund TI, Gabrielsson S. Exosomes from antigen-pulsed dendritic cells induce stronger antigen-specific immune responses than microvesicles in vivo. *Sci Rep*. 2017;7(1):17095. <https://doi.org/10.1038/s41598-017-16609-6>.
 28. Huang F, Wan J, Hu W, Hao S. Enhancement of anti-leukemia immunity by leukemia-derived exosomes via downregulation of TGF-beta1 expression. *Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology*. 2017;44(1):240–54. <https://doi.org/10.1159/000484677>.
 29. Bhatnagar S, Shinagawa K, Castellino FJ, Schorey JS. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. *Blood*. 2007;110(9):3234–44. <https://doi.org/10.1182/blood-2007-03-079152>.
 30. Qazi KR, Torregrosa Paredes P, Dahlberg B, Grunewald J, Eklund A, Gabrielsson S. Proinflammatory exosomes in bronchoalveolar lavage fluid of patients with sarcoidosis. *Thorax*. 2010;65(11):1016–24. <https://doi.org/10.1136/thx.2009.132027>.
 31. Kato T, Miyaki S, Ishitobi H, Nakamura Y, Nakasa T, Lotz MK, et al. Exosomes from IL-1beta stimulated synovial fibroblasts induce osteoarthritic changes in articular chondrocytes. *Arthritis Res Ther*. 2014;16(4):R163. <https://doi.org/10.1186/ar4679>.
 32. Wen SW, Sceneay J, Lima LG, Wong CS, Becker M, Krumeich S, et al. The biodistribution and immune suppressive effects of breast cancer-derived exosomes. *Cancer Res*. 2016;76(23):6816–27. <https://doi.org/10.1158/0008-5472.can-16-0868>.
 33. Schuler PJ, Saze Z, Hong CS, Muller L, Gillespie DG, Cheng D, et al. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. *Clin Exp Immunol*. 2014;177(2):531–43. <https://doi.org/10.1111/cei.12354>.
 34. Bretz NP, Ridinger J, Rupp AK, Rimbach K, Keller S, Rupp C, et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via toll-like receptor signaling. *J Biol Chem*. 2013;288(51):36691–702. <https://doi.org/10.1074/jbc.M113.512806>.
 35. Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. *Int J Cancer*. 2009;124(11):2621–33. <https://doi.org/10.1002/ijc.24249>.
 36. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. *Haematologica*. 2011;96(9):1302–9. <https://doi.org/10.3324/haematol.2010.039743>.
 37. Liu Y, Xiang X, Zhuang X, Zhang S, Liu C, Cheng Z, et al. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. *Am J Pathol*. 2010;176(5):2490–9. <https://doi.org/10.2353/ajpath.2010.090777>.
 38. Tian X, Ma J, Wang T, Tian J, Zhang Y, Mao L, et al. Long non-coding RNA HOXA transcript antisense RNA myeloid-specific 1-HOXA1 axis downregulates the immunosuppressive activity of myeloid-derived suppressor cells in lung Cancer. *Front Immunol*. 2018;9:473. <https://doi.org/10.3389/fimmu.2018.00473>.
 39. Wang Y, Tian J, Tang X, Rui K, Tian X, Ma J, et al. Exosomes released by granulocytic myeloid-derived suppressor cells attenuate DSS-induced colitis in mice. *Oncotarget*. 2016;7(13):15356–68. <https://doi.org/10.18632/oncotarget.7324>.
 40. Yu X, Huang C, Song B, Xiao Y, Fang M, Feng J, et al. CD4+ CD25+ regulatory T cells-derived exosomes prolonged kidney allograft survival in a rat model. *Cell Immunol*. 2013;285(1–2):62–8. <https://doi.org/10.1016/j.cellimm.2013.06.010>.

41. Bang C, Thum T. Exosomes: new players in cell-cell communication. *Int J Biochem Cell Biol.* 2012;44(11):2060–4. <https://doi.org/10.1016/j.biocel.2012.08.007>.
42. Mathivanan S, Fahner CJ, Reid GE, Simpson RJ. ExoCarta 2012: database of exosomal proteins, RNA and lipids. *Nucleic Acids Res.* 2012;40(Database issue):D1241–4. <https://doi.org/10.1093/nar/gkr828>.
43. Mathivanan S, Simpson RJ. ExoCarta: a compendium of exosomal proteins and RNA. *Proteomics.* 2009;9(21):4997–5000. <https://doi.org/10.1002/pmic.200900351>.
44. Record M, Carayon K, Poirot M, Silvente-Poirot S. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiological processes. *Biochim Biophys Acta.* 2014;1841(1):108–20. <https://doi.org/10.1016/j.bbailip.2013.10.004>.
45. Osteikoetxea X, Balogh A, Szabo-Taylor K, Nemeth A, Szabo TG, Palocz K, et al. Improved characterization of EV preparations based on protein to lipid ratio and lipid properties. *PLoS One.* 2015;10(3):e0121184. <https://doi.org/10.1371/journal.pone.0121184>.
46. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol.* 2007;9(6):654–9. <https://doi.org/10.1038/ncb1596>.
47. Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. *Nucleic Acids Res.* 2012;40(21):10937–49. <https://doi.org/10.1093/nar/gks832>.
48. Nolte-t Hoen EN, Buermans HP, Waasdorp M, Stoorvogel W, Wauben MH, t Hoen PA. Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. *Nucleic Acids Res.* 2012;40(18):9272–85. <https://doi.org/10.1093/nar/gks658>.
49. Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. *Cell Res.* 2015;25(8):981–4. <https://doi.org/10.1038/cr.2015.82>.
50. Gutzeit C, Nagy N, Gentile M, Lyberg K, Gumz J, Vallhov H, et al. Exosomes derived from Burkitt's lymphoma cell lines induce proliferation, differentiation, and class-switch recombination in B cells. *J Immunol (Baltimore, Md : 1950).* 2014;192(12):5852–62. <https://doi.org/10.4049/jimmunol.1302068>.
51. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. *J Immunol (Baltimore, Md : 1950).* 2001;166(12):7309–18.
52. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. *J Cell Biol.* 1999;147(3):599–610.
53. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. *Nat Med.* 1998;4(5):594–600.
54. Saunderson SC, Dunn AC, Crocker PR, McLellan AD. CD169 mediates the capture of exosomes in spleen and lymph node. *Blood.* 2014;123(2):208–16. <https://doi.org/10.1182/blood-2013-03-489732>.
55. Wiklander OP, Nordin JZ, O'Loughlin A, Gustafsson Y, Corso G, Mager I, et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. *J Extracell Vesicles.* 2015;4:26316. <https://doi.org/10.3402/jev.v4.26316>.
56. Tian T, Zhang HX, He CP, Fan S, Zhu YL, Qi C, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. *Biomaterials.* 2018;150:137–49. <https://doi.org/10.1016/j.biomaterials.2017.10.012>.
57. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. *J Immunol (Baltimore, Md : 1950).* 2002;168(7):3235–41.
58. van der Vlist EJ, Arkesteijn GJ, van de Lest CH, Stoorvogel W, Nolte-t' Hoen EN, Wauben MH. CD4(+) T cell activation promotes the differential release of distinct populations of nanosized vesicles. *J Extracell Vesicles.* 2012;1 <https://doi.org/10.3402/jev.v1i0.18364>.
59. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/complex. *J Immunol.* 2002;168(7):3235–41. <https://doi.org/10.4049/jimmunol.168.7.3235>.
60. Baek H, Ye M, Kang GH, Lee C, Lee G, Choi DB, et al. Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer's disease model. *Oncotarget.* 2016;7(43):69347–57. <https://doi.org/10.18632/oncotarget.12469>.
61. Agarwal A, Fanelli G, Letizia M, Tung SL, Boardman D, Lechler R, et al. Regulatory T cell-derived exosomes: possible therapeutic and diagnostic tools in transplantation. *Front Immunol.* 2014;5:555. <https://doi.org/10.3389/fimmu.2014.00555>.
62. Smyth LA, Ratnasothy K, Tsang JY, Boardman D, Warley A, Lechler R, et al. CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function. *Eur J Immunol.* 2013;43(9):2430–40. <https://doi.org/10.1002/eji.201242909>.
63. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. *J Immunol (Baltimore, Md : 1950).* 2011;187(2):676–83. <https://doi.org/10.4049/jimmunol.1003884>.
64. Yang Y, Bucan V, Baehre H, von der Ohe J, Otte A, Hass R. Acquisition of new tumor cell properties by MSC-derived exosomes. *Int J Oncol.* 2015;47(1):244–52. <https://doi.org/10.3892/ijo.2015.3001>.
65. Beckett K, Monier S, Palmer L, Alexandre C, Green H, Bonheil E, et al. Drosophila S2 cells secrete wingless on exosome-like vesicles but the wingless gradient forms independently of exosomes. *Traffic (Copenhagen, Denmark).* 2013;14(11):82–96. <https://doi.org/10.1111/tra.12016>.
66. Abrami L, Brandi L, Moayeri M, Brown MJ, Krantz BA, Leppla SH, et al. Hijacking multivesicular bodies enables long-term and exosome-mediated long-distance action of anthrax toxin. *Cell Rep.* 2013;5(4):986–96. <https://doi.org/10.1016/j.celrep.2013.10.019>.
67. Hoshino D, Kirkbride KC, Costello K, Clark ES, Sinha S, Grega-Larson N, et al. Exosome secretion is enhanced by invadopodia and drives invasive behavior. *Cell Rep.* 2013;5(5):1159–68. <https://doi.org/10.1016/j.celrep.2013.10.050>.
68. Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R, et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. *Oncogene.* 2015;34(3):290–302. <https://doi.org/10.1038/ncr.2013.560>.
69. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. *Nat Cell Biol.* 2012;14(7):677–85. <https://doi.org/10.1038/ncb2502>.
70. Budhu S, Schaer DA, Li Y, Toledo-Crow R, Panageas K, Yang X, et al. Blockade of surface-bound TGF-beta on regulatory T cells abrogates suppression of effector T cell function in the tumor

- microenvironment. *Sci Signal*. 2017;10(494):eaak9702. <https://doi.org/10.1126/scisignal.aak9702>.
71. Kapur R, Kim M, Aslam R, McVey MJ, Tabuchi A, Luo A, et al. T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10. *Blood*. 2017;129(18):2557–69. <https://doi.org/10.1182/blood-2016-12-758185>.
 72. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. *J Immunol* (Baltimore, Md : 1950). 2005;174(10):6440–8.
 73. Cai Z, Zhang W, Yang F, Yu L, Yu Z, Pan J, et al. Immunosuppressive exosomes from TGF-beta1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. *Cell Res*. 2012;22(3):607–10. <https://doi.org/10.1038/cr.2011.196>.
 74. Zhang H, Xie Y, Li W, Chibbar R, Xiong S, Xiang J. CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity. *Cell Mol Immunol*. 2011;8(1):23–30. <https://doi.org/10.1038/cmi.2010.59>.
 75. Xie Y, Zhang H, Li W, Deng Y, Munegowda MA, Chibbar R, et al. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity. *J Immunol*. 2010;185(9):5268–78. <https://doi.org/10.4049/jimmunol.1000386>.
 76. Nazimek K, Ptak W, Nowak B, Ptak M, Askenase PW, Bryniarski K. Macrophages play an essential role in antigen-specific immune suppression mediated by T CD8(+) cell-derived exosomes. *Immunology*. 2015;146(1):23–32. <https://doi.org/10.1111/imm.12466>.
 77. Bryniarski K, Ptak W, Jayakumar A, Pullmann K, Caplan MJ, Chairoungdua A, et al. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. *J Allergy and Clin Immunol*. 2013;132(1):170–81. <https://doi.org/10.1016/j.jaci.2013.04.048>.
 78. DeRita RM, Zerlanko B, Singh A, Lu H, Iozzo RV, Benovic JL, et al. C-Src, insulin-like growth factor I receptor, G-protein-coupled receptor kinases and focal adhesion kinase are enriched into prostate cancer cell exosomes. *J Cell Biochem*. 2017;118(1):66–73. <https://doi.org/10.1002/jcb.25611>.
 79. Wahlgren J, Karlson Tde L, Glader P, Telemo E, Valadi H. Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling. *PLoS One*. 2012;7(11):e49723. <https://doi.org/10.1371/journal.pone.0049723>.
 80. Peters PJ, Borst J, Oorschot V, Fukuda M, Krahenbuhl O, Tschopp J, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. *J Exp Med*. 1991;173(5):1099–109.
 81. Tumne A, Prasad VS, Chen Y, Stolz DB, Saha K, Ratner DM, et al. Nucleocytoplasmic suppression of human immunodeficiency virus type 1 transcription by exosomes secreted from CD8+ T cells. *J Virol*. 2009;83(9):4354–64. <https://doi.org/10.1128/JVI.02629-08>.
 82. Durlanik S, Loyal L, Stark R, Sercan Alp O, Hartung A, Radbruch A, et al. CD40L expression by CD4+ but not CD8+ T cells regulates antiviral immune responses in acute LCMV infection in mice. *Eur J Immunol*. 2016;46(11):2566–73. <https://doi.org/10.1002/eji.201646420>.
 83. Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, et al. ICOS promotes the function of CD4+ effector T cells during anti-OX40-mediated tumor rejection. *Cancer Res*. 2016;76(13):3684–9. <https://doi.org/10.1158/0008-5472.can-15-3412>.
 84. Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q, et al. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. *J Immunol* (Baltimore, Md : 1950). 2012;188(12):5954–61. <https://doi.org/10.4049/jimmunol.1103466>.
 85. Kaur S, Singh SP, Elkahloun AG, Wu W, Abu-Asab MS, Roberts DD. CD47-dependent immunomodulatory and angiogenic activities of extracellular vesicles produced by T cells. *Matrix Biology: Journal of the International Society for Matrix Biology*. 2014;37:49–59. <https://doi.org/10.1016/j.matbio.2014.05.007>.
 86. Min H, Sun X, Yang X, Zhu H, Liu J, Wang Y, et al. Exosomes derived from irradiated esophageal carcinoma-infiltrating T cells promote metastasis by inducing the epithelial-mesenchymal transition in esophageal Cancer cells. *Pathol Oncol Res: POR*. 2017;24:11–8. <https://doi.org/10.1007/s12253-016-0185-z>.
 87. Bosque A, Dietz L, Gallego-Lleyda A, Sanclemente M, Iturralde M, Naval J, et al. Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein. *Oncotarget*. 2016;7(20):29287–305. <https://doi.org/10.18632/oncotarget.8678>.
 88. Tucci M, Passarelli A, Mannavola F, Stucci LS, Ascierio PA, Capone M, et al. Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. *Oncimmunology*. 2018;7(2):e1387706. <https://doi.org/10.1080/2162402x.2017.1387706>.
 89. Rodriguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. *Mol Cancer*. 2017;16(1):156. <https://doi.org/10.1186/s12943-017-0726-4>.
 90. Vojtech L, Woo S, Hughes S, Levy C, Ballweber L, Sauteraud RP, et al. Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions. *Nucleic Acids Res*. 2014;42(11):7290–304. <https://doi.org/10.1093/nar/gku347>.
 91. Zlotogorski-Hurvitz A, Dayan D, Chaushu G, Korvala J, Salo T, Sommunen R, et al. Human saliva-derived exosomes: comparing methods of isolation. *The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society*. 2015;63(3):181–9. <https://doi.org/10.1369/0022155414564219>.
 92. Gunasekaran M, Xu Z, Nayak DK, Sharma M, Hachem R, Walia R, et al. Donor-derived exosomes with lung self-antigens in human lung allograft rejection. *Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg*. 2017;17(2):474–84. <https://doi.org/10.1111/ajt.13915>.
 93. Atay S, Banskota S, Crow J, Sethi G, Rink L, Godwin AK. Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. *Proc Natl Acad Sci U S A*. 2014;111(2):711–6. <https://doi.org/10.1073/pnas.1310501111>.
 94. Munster M, Fremder E, Miller V, Ben-Tsedek N, Davidi S, Scherer SJ, et al. Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles. *PLoS One*. 2014;9(4):e95983. <https://doi.org/10.1371/journal.pone.0095983>.
 95. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature*. 2015;523(7559):177–82. <https://doi.org/10.1038/nature14581>.
 96. Kornek M, Lynch M, Mehta SH, Lai M, Exley M, Afdhal NH, et al. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. *Gastroenterology*. 2012;143(2):448–58. <https://doi.org/10.1053/j.gastro.2012.04.031>.
 97. Marino J, Babiker-Mohamed MH, Crosby-Bertorini P, Paster JT, LeGuern C, Germana S, et al. Donor exosomes rather than passenger leukocytes initiate alloreactive T cell responses after transplantation. *Science. Immunology*. 2016;1(1) <https://doi.org/10.1126/sciimmunol.aaf8759>.

98. Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. *Blood*. 2017;130(23):2569–72. <https://doi.org/10.1182/blood-2017-08-802413>.
99. Shi L, Mai S, Israels S, Browne K, Trapani JA, Greenberg AH. Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. *J Exp Med*. 1997;185(5):855–66.
100. Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in *Danio rerio*. *Pharm Res*. 2015;32(6):2003–14. <https://doi.org/10.1007/s11095-014-1593-y>.
101. Tang XJ, Sun XY, Huang KM, Zhang L, Yang ZS, Zou DD, et al. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. *Oncotarget*. 2015;6(42):44179–90. <https://doi.org/10.18632/oncotarget.6175>.
102. Admyre C, Bohle B, Johansson SM, Focke-Tejkl M, Valenta R, Scheynius A, et al. B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines. *The Journal of Allergy and Clinical Immunology*. 2007;120(6):1418–24. <https://doi.org/10.1016/j.jaci.2007.06.040>.
103. Papp K, Vegh P, Prechl J, Kerekes K, Kovacs J, Csikos G, et al. B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity. *Mol Immunol*. 2008;45(8):2343–51. <https://doi.org/10.1016/j.molimm.2007.11.021>.
104. Lugini L, Cecchetti S, Huber V, Luciani F, Macchia G, Spadaro F, et al. Immune surveillance properties of human NK cell-derived exosomes. *J Immunol (Baltimore, Md : 1950)*. 2012;189(6):2833–42. <https://doi.org/10.4049/jimmunol.1101988>.